Interest in the antimicrobial therapy of acute enteric fever has been revived after the occurrence of outbreaks caused by chloramphenicolresistant Salmonella typhi in Mexico, the United States, and other parts of the world (1, 4, 11) . Only two additional antimicrobial agents, ampicillin and cotrimoxazole, are generally considered useful in the treatment of this infection (8, 17) . Recently, Pillay et al. claimed amoxycillin to be another alternative therapeutic agent (12) . Some of the chloramphenicolresistant S. typhi isolates were also found to be resistant to ampicillin and sulfonamides (1, 11) , and it is uncertain whether cotrimoxazole will prove effective in infections caused by organisms highly resistant to sulfonamides.
It is a well-recognized, yet poorly understood, fact that not all antimicrobial agents active in vitro against S. typhi or S. paratyphi are necessarily effective in the treatment of the clinical disease (5, 8) . This lack of correlation between the results ofthe in vitro and the in vivo studies may have been related to a number of factors, including the patterns of serum antibacterial activity achieved with the dosage regimens used. The possibility that inadequate serum antibiotic concentration was an important cause of the relatively high incidence of treatment failures reported with oral, but not parenteral, ampicillin therapy has not been alto- ' gether excluded (9, 11, 14) . These issues and their practical implications have been discussed previously (16) . Cefazolin, when compared with other cephalosporin antibiotics, has been demonstrated to yield significantly higher and better sustained blood levels after either intramuscular (i.m.) or intravenous (i.v.) administration (10) . Preliminary in vitro studies conducted in this laboratory have shown that the minimal inhibitory concentrations (MIC) of this antibiotic against eleven locally isolated strains of chloramphenicol and ampicillin-susceptible S. typhi and S. paratyphi B ranged between 0.80 and 3.12 ,Ag/ ml, suggesting that very high serum antibacterial activity against salmonellae may be expected in patients receiving the recommended antibiotic dosage. The purpose ofthis study was to evaluate the efficacy of cefazolin in the treatment of acute enteric fever, as monitored by serum antibiotic level and serum inhibitory activity determinations.
MATERIALS AND METHODS
Only patients with acute enteric fever, proven by positive blood cultures, were selected for this study. Blood for culture was collected in tryptose phosphate broth (BBL), and bottles were incubated at 37 C. Rectal swabs were streaked on salmonella-shigella (BBL) and MacConkey agar (Difco) plates and were inoculated in Selenite cystine broth (BBL). Final identification of Salmonella was based on carbohydrate fermentation patterns and slide agglutination tests, according to standard procedures (6 Assay of cefazolin concentrations was performed by the two-layer cylinder-plate method using antibiotic medium 5 (Difco) after adjusting its pH to 6.0. A Bacillus 8ubtili8 spore suspension (Difco) served as the test organism. Serum antibacterial activity was determined by the twofold dilution technique (2). For comparative purposes, both pooled normal human serum and Mueller-Hinton broth (BBL) were used as diluents. The inoculum was a 1O-4 dilution of an overnight broth culture (final concentration, approximately 105 organisms/ml). After overnight incubation, the highest serum dilution inhibiting visible growth was recorded. Clear tubes were subcultured on MacConkey agar plates using a 0.01-ml calibrated loop. The highest dilution from which no more than one colony grew was regarded as the highest bactericidal dilution. Other laboratory tests done on every patient before, during, and after the treatment course included urinalysis, complete blood count, blood urea nitrogen, and serum creatinine. In addition, serum electrolyte and liver function tests were done whenever indicated.
RESULTS
Patients. Nine patients, five females and four males, ranging in age between 15 and 32 years, were selected for this trial. All presented with the classic clinical picture of acute enteric fever. The duration of the febrile illness prior to initiating antibiotic therapy varied between 4 and 12 days, and the peak temperatures ranged between 39.7 and 41.0 C. Pretreatment blood cultures from seven patients grew S. typhi, and from the other two S. paratyphi B grew. Serum creatinine values were normal in all subjects. Leukocyte counts were either normal or low, consistent with the diagnosis of acute enteric fever. None of the patients showed evidence of intestinal hemorrhage or perforation.
In vitro susceptibility tests. All Salmonella isolates recovered from the nine patients proved to be susceptible to cefazolin, ampicillin, and chloramphenicol. The results of inhibition zone sizes, together with MIC and minimal bactericidal concentration values of the three antibiotics against the nine isolates, are given in Table 1 . It is clear that the inhibitory concentrations are readily achievable in sera of patients receiving the regularly recommended dosages of any of the three antibiotics. In contrast to the bacteriostatic effect of chloramphenicol, the bactericidal effects of cefazolin and ampicillin were demonstrated by MIC and minimal bactericidal concentration values that were essentially identical.
Treatment regimens. In eight patients, cefazolin was administered initially by the i.v. route. In four patients this was continued until treatment was completed, but in the rest the occurrence of severe pain necessitated a change to the i.m. route 8 to 14 days after starting therapy. One patient received the antibiotic i.m. throughout the entire treatment course. Probenicid was given to one patient (number 8) in a dose of 0.5 g every 6 h, starting on day 6 of cefazolin therapy. The details of the antibiotic regimens are summarized in Table 2 .
Serum cefazolin concentrations and serum antibacterial activity. Serum peak and trough cefazolin concentrations and highest serum bacteriostatic and bactericidal dilutions are outlined in Table 2 . The mean peak serum cefazolin concentration after a 0.5-g i.v. injection was 64.4 ,ug/ml and the mean trough concentration, 3 h later, was 12.7 ug/ml. Thus, serum antibiotic concentration was continuously maintained well above the MIC value against the infecting organism. This was also confirmed by the results of serum inhibitory activity determinations. The serum inhibitory dilution (static effect) at peak level was frequently 1/64, and at trough level it was either 1/16 or 1/ 32. Serum antibacterial activity was more pronounced when the samples were diluted in pooled normal serum rather than in broth. This may be attributed to the nonspecific inhibitory factors present in normal serum, which itself produced bacteriostatic and bactericidal effects in a dilution of 1/4 (in broth). The mean serum cefazolin concentration after a 1.0-g i.v. dose was about twice that obtained with a 0.5-g dose. The only exception was encountered in the first (15) . This might suggest that well-sustained serum antibacterial activity is advantageous for satisfactory control of the typhoidal infection. Studies conducted in this laboratory on typhoid patients receiving chloramphenicol in a dose of 750 mg by mouth every 6 h revealed that the peak inhibitory serum dilution was 1/16 to 1/32 and the trough inhibitory dilution was 1/8 to 1/16. These results are similar to the data obtained with cefazolin reported in this study, although the peak inhibitory activity produced by cefazolin was frequently higher.
The relative efficacy of cefazolin in acute enteric fever and specific recommendations regarding its optimal dosage regimen should await more extensive studies that would consider, among other parameters, the incidence of the chronic carrier state after acute infection. In this respect, cefazolin offers the advantage of reaching bile in very high concentrations (13) . Possibly, the high frequency and severity of troublesome phlebitis complicating treatment 
